smithkline beecham corporation and smithkline beecham,collectively smithkline brought suit against apotex corporation,apotex,and torpharm,collectively apotex for infringement of smithkline patent,patent patent.apotex moved for summary judgment,arguing that the patent was invalid.the district court granted summary judgment to apotex.we agree that the claims of the patent are invalid and thus affirm.
background 
this case presents the question whether smithkline product patent for paroxetine,patent filed,patent,anticipated its patent claiming paroxetine made by an allegedly novel process.smithkline patent claimed a pharmaceutical product aimed at treating depression.in smithkline own words,the patent disclose d a pharmaceutical composition in tablet form containing paroxetine.the patent also disclosed that the product is usually presented as a unit dose composition containing from to mg,more usually from to mg,for example to mg such as,or mg.patent,ll.
in,smithkline obtained approval from the food and drug administration fda to market crystalline paroxetine hydrochloride,which it began to sell under the trade name paxil.smithkline then filed various other related patent applications,including application no,on december,which eventually matured into the patent.the patent contained the following two claims 
claim.a pharmaceutical composition in tablet form containing paroxetine,produced on a commercial scale by a process which comprises the steps of 
a dry admixing paroxetine and excipients in a mixer to form a mixture or 
b dry admixing paroxetine and excipients,compressing the resulting combination into a slug material or roller compacting the resulting combination into a strand material,and milling the prepared material into a free flowing mixture and 
c compressing the mixture into tablets.
claim.a pharmaceutical composition in tablet form according to claim containing an amount of paroxetine selected from mg,mg,mg,mg and mg,wherein the amount of paroxetine is expressed as the free base,produced on a commercial scale by a process which comprises the steps of 
a dry admixing paroxetine and excipients in a mixer to form a mixture or 
b dry admixing paroxetine and excipients,compressing the resulting combination into a slug material or roller compacting the resulting combination into a strand material,and milling the prepared material into a free flowing mixture and 
c compressing the mixture into tablets using a single punch or rotary tablet machine.
certificate of correction.
on march,apotex,a generic drug manufacturer and defendant here,submitted an abbreviated new drug application anda to the fda,seeking approval to market a generic version of paxil.in connection with its anda,apotex filed a paragraph iv certification,which is a statement by the applicant that designated patents claiming either the drug or a use of the drug at issue are invalid or will not be infringed by the applicant.j a vii iv.apotex paragraph iv certification claimed that the patent was invalid.pursuant to e,which makes submitting an anda an act of infringement,smithkline brought suit against apotex,alleging infringement of the patent.apotex counterclaimed that the patent was invalid and in due course moved for summary judgment of invalidity.
in its decision,the district court held the patent anticipated and thus invalid.the district court appeared to view the question of anticipation as turning on the scope of the patent,namely whether the patent should be viewed as claiming paroxetine without regard to the process by which it was made or whether the process steps were to be treated as claim limitations.the district court perceived a conflict in this respect between our decisions in scripps clinic research foundation genentech,which the district court viewed as holding that the process steps were not claim limitations and atlantic thermoplastics,faytex,which the district court viewed as holding that the process steps were claim limitations.the district court concluded that it was bound to follow the earlier scripps decision,finding that scripps required it to evaluate the validity of the patent claims by reference to the products claimed therein,without the process limitations of those claims.because the patent disclosed tablets containing paroxetine,including in the dosages specified in claim of the patent,the court determined that the patent anticipated the patent.
in holding the patent anticipated,the district court found that the product claimed by the patent was the same product disclosed by the patent,despite smithkline arguments that the paroxetine tablets claimed by the patent were different because they lacked a pink hue,did not contain spherical granules,and had a different content uniformity.the court stated that these characteristics were not required by the patent claims or specification and that the product characteristics now cited by smithkline are insufficient to distinguish the product of the patent from the products claimed in the patent.the court therefore granted apotex summary judgment motion.pursuant to.b,the court entered a separate judgment with respect to the invalidity of the patent.smithkline timely appealed.we have jurisdiction pursuant to a.
discussion 
on appeal,smithkline argues that the district court improperly ignored the process limitations of the two claims in the patent when it determined validity.smithkline br.at.in other words,if the district court had treated the process steps recited in the patent as claim limitations,it would have found that the patent did not anticipate the patent,or that there was a genuine issue of fact over whether the patent disclosed those process limitations.
smithkline misunderstands the nature of anticipation.as set forth below,once a product is fully disclosed in the art,future claims to that same product are precluded,even if that product is claimed as made by a new process.
a claim is one in which the product is defined at least in part in terms of the method or process by which it is made.bonito boats,thunder craft boats,d quoting chisum,patents,at.while the patent statute does not provide for claims,the courts have long recognized the appropriateness of such claims.see,in re thorpe,in re brown,in re steppan.the purpose of claims is to allow inventors to claim an otherwise patentable product that resists definition by other than the process by which it is made.in re thorpe,at.thus,an inventor will not be foreclosed from the benefits of the patent system simply because a product is difficult to describe in words,or its structure is insufficiently understood.today,however,claims are used by inventors even if the invention could have been described independent of the process 
this court has previously considered the scope of claims.in scripps,we held that the claims at issue were not limited by the process steps within those claims.at.there,the patent concerned a protein,factor viii c,essential to blood clotting.id.at.the patent contained claims directed at the product made in accordance with a particular process,also claimed in the patent.id.at.the court found that factor viii c that was produced by a different process would nonetheless infringe the claims because 
in determining patentability we construe the product as not limited by the process stated in the claims.since claims must be construed the same way for validity and for infringement,the correct reading of the claims is that they are not limited to product prepared by the process set forth in the claims.
a year later this court decided atlantic thermoplastics.there,we held that the process steps in a claim do serve as claim limitations.at.the patent in atlantic thermoplastics concerned shock absorbing shoe innersoles.id.at.the patentee argued that the defendant had infringed its claim.id.at.finding that the accused products were made by a different process than that claimed in the patent claim,the court determined that the patent did not extend to cover the product as made by any process.id.at.this court stated that i n light of supreme court caselaw and the history of claims,this court acknowledges that infringement analysis proceeds with reference to the patent claims.thus,process terms in claims serve as limitations in determining infringement.id.
a sharply divided court denied rehearing en banc of atlantic thermoplastics,with four judges dissenting in four separate opinions.see,rehearing en banc denied,concurring opinion,dissenting opinions.judge newman,joined by judges rich and lourie,urged that the panel in atlantic thermoplastics had incorrectly adopted a blanket rule that the process steps of a claim should be automatically treated as claim limitations.at.in their view,the process steps should sometimes be treated as claim limitations and sometimes not,depending on the class of claim at issue.id.at.
some commentators,like the district court here,have perceived a conflict between scripps,where the court construed the claims without reference to the process steps,and atlantic thermoplastics,where the court read the process steps as claim limitations we need not address this controversy here.the issue here does not turn on how broadly or narrowly we construe the patent claims,for it is undisputed that the product that is the subject of the patent claims is paroxetine.rather the issue is whether the patent anticipated the patent,when the patent broadly claimed paroxetine without regard to the process by which it was made thus,the ultimate issue is simply whether the prior art disclosure of a product precludes a future claim to that same product when it is made by an allegedly novel process 
regardless of how broadly or narrowly one construes a claim,it is clear that such claims are always to a product,not a process.it has long been established that one can not avoid anticipation by an earlier product disclosure by claiming the same product more narrowly,that is,by claiming the product as produced by a particular process.this was the exact issue in in re thorpe.there,the patent concerned a composition that was used in carbonless copy paper systems.at.the composition was known in the prior art,but was previously made using zinc dibenzoate.in a claim,thorpe claimed the same composition made by a process that used zinc oxide and benzoic acid,rather than zinc dibenzoate.the court upheld the pto rejection of the claim.id.at.it held that i f the product in a claim is the same as or obvious from a product of the prior art,the claim is unpatentable even though the prior product was made by a different process.id.at.in re thorpe has never been overruled and has been followed for many years by the pto the current mpep states 
even though claims are limited by and defined by the process,determination of patentability is based on the product itself.the patentability of a product does not depend on its method of production.if the product in the claim is the same as or obvious from a product of the prior art,the claim is unpatentable even though the prior product was made by a different process.
mpep,may quoting in re thorpe,at.
at the time of in re thorpe,the rule as articulated was hardly new.long before in re thorpe,our predecessor court,the court of customs and patent appeals,consistently held that claims could not validly claim products already known in the art.see in re fessmann,in re johnson,in re stephens,we think it well settled that the presence of process limitations in product claims,which product does not otherwise patentably distinguish over the prior art,can not impart patentability to that product.in re dilnot,the addition of a method step in a product claim,which product is not patentably distinguishable from the prior art,can not impart patentability to the old product.in re moeller,t he article itself must be inventive and patentably distinct from such articles disclosed in the prior art.in re ewert,in re brawn,in re harvey.
this rule is also supported by earlier supreme court cases.for example,in cochrane badische anilin soda fabrik.basf,natural alizarine was already known in the art.id.at.however,basf obtained a patent covering artificial alizarine,as produced by a bromine reaction process.id.at.the accused infringer,cochrane,then sold artificial alizarine made by a different,sulfuric acid reaction process.id.at.the court reasoned that if the basf patent were construed to cover the product itself,it would be invalid because the product was old.id.at.the court stated that w hile a new process for producing it was patentable,the product itself could not be patented,even though it was a product made artificially for the first time id.at.as the atlantic thermoplastics panel recognized,the basf court thus held that a patent applicant could not obtain exclusive rights to a product in the prior art by adding a process limitation to the product claim.atlantic thermoplastics,at citing basf,at.see also containers,united states,cert.denied,d following basf,and stating that the addition of a method step in a product claim,which product is not patentably distinguishable from the prior art,can not impart patentability to the old product.this understanding of basf has been recognized by leading commentators.see,chisum on patents ed.citing basf for the proposition that e ven through a product may be claimed in terms of the process of making it,the product still must be new in structural terms in order to meet the novelty requirement.other supreme court cases have reached the same conclusion.see wabash appliance.although in some instances a claim may validly describe a new product with some reference to the method of production,a patentee who does not distinguish his product from what is old except by reference,express or constructive,to the process by which he produced it,can not secure a monopoly on the product by whatever means produced.patent,wall.
as this history of cases from the supreme court,our court,and our predecessor court make clear,anticipation by an earlier product patent can not be avoided by claiming the same product more narrowly in a claim.it makes no difference here whether the patent claims are construed broadly to cover the product made by any process or narrowly to cover only the product made by a dry admixing process.either way,anticipation by an earlier product disclosure which disclosed the product itself can not be avoided.while the process set forth in the claim may be new,that novelty can only be captured by obtaining a process claim.we agree with the district court conclusion that the patent disclosure anticipated the identical product claimed by the patent even though that product was produced by an allegedly novel process 
in the district court,the parties differed on a second issue,that is,whether the product produced by the process claimed in the patent was,in fact,a different product than that disclosed in the patent.if those claims produced a different product than that disclosed by the patent,there would be an argument that the patent disclosure did not anticipate.in re luck.on this appeal,in response to apotex argument that the issue had been waived by failure to include it in the opening brief,smithkline did not point out in its reply brief where the issue had been presented in its opening brief.questioned by this court at oral argument as to whether this second issue has been properly preserved on appeal,smithkline urged that it had raised this issue on appeal and was challenging the district court finding regarding the novelty of the product claimed by the patent.we conclude that this issue has been waived for failure to brief it on appeal.
our law is well established that arguments not raised in the opening brief are waived.see cross med,medtronic sofamor danek.smithkline opening brief focused on the perceived conflict between scripps and atlantic thermoplastics to the exclusion of arguments that the product produced by the allegedly novel process was novel.indeed,smithkline argued that this court should address only the issue that provided the basis for the district incorrect interpretation of the claims of the patent.smithkline br.at.smithkline failed to include in the argument section of its opening brief an argument that,contrary to the district court finding,the product claimed in the patent is itself different from that disclosed in the patent.to be sure,there are various places in its opening brief where smithkline alluded that the paroxetine tablets claimed in the patent were different from tablets disclosed in the prior art and expressed its disagreement with the district court determination that the product produced by the patent was not new.in its argument section,smithkline stated there were numerous factual disputes between the parties,including the scope and content of the prior art,and the unexpected improvement of the claimed invention over the prior art.smithkline br.at.similarly,on page of its brief,smithkline stated 
here,the district court held that the product of the patent can not be distinguished from the paroxetine tablets in the prior art.accordingly,although sb disagrees with that determination,if the district court was determined to follow scripps,it should have then considered the process limitations of the claims of the patent as essential limitations in determining validity.
smithkline br.at emphasis added in a footnote to this sentence,smithkline further noted that the patent tablets have a significantly reduced tendency to pink,and have a different fingerprint than tablets made by a prior art wet granulation process.the district court erroneously believed it did not need to consider such differences because they were not literally recited in the claim.this was an error of law.id.at.this footnote is the only statement that even approaches a substantive argument on novelty in the entire argument section of smithkline opening brief.
we find that these mere statements of disagreement with the district court as to the existence of factual disputes do not amount to a developed argument.see,anderson city of boston,cir when a party includes no developed argumentation on a point we treat the argument as waived under our well established rule.tolbert queens,cir it is a settled appellate rule that issues adverted to in a perfunctory manner,unaccompanied by some effort at developed argumentation,are deemed waived.internal quotation marks omitted united states elder,cir same laborers int l union of am.foster wheeler,cir,cert denied,d an issue is waived unless a party raises it in its opening brief,and for those purposes a passing reference to an issue will not suffice to bring that issue before this court.quoting simmons city of philadelphia,cir,cert.denied,d united states dunkel,cir a skeletal argument,really nothing more than an assertion,does not preserve a claim especially not when the brief presents a passel of other arguments judges are not like pigs,hunting for truffles buried in briefs.
further,arguments raised in footnotes are not preserved.see cross med,at holding that an argument raised in a footnote in an opening brief was waived as not properly raised fuji photo film jazz photo,finding that an argument raised in a footnote in an opening brief and then more fully in the reply brief,was not properly raised graphic controls utah med,finding that an argument raised in a footnote which in turn referenced the full argument in the appendix was not preserved citing fed.of app.a which then stated that t he argument in the appellant brief must contain the contentions of the appellant on the issues presented,and the reasons therefor,with citations to the authorities and parts of the record relied on 
therefore,smithkline has not established that the district court erred in its ultimate judgment holding the patent anticipated by the patent.
conclusion 
for the foregoing reasons,the decision below is affirmed.
the law of anticipation does not change in the special situation where claims contain both product and process limitations.the panel majority perpetuates a confusing misunderstanding of precedent governing claims,ignoring the opportunity and need for clarification.
in this case the district court found anticipation based on a claim construction that erased critical limitations of the claim.at issue are claims that require the use of a specified process for the commercial production of tablets of the known pharmaceutical product paroxetine paxil.the claims are simple and straightforward,and state the processing steps that produce the stabilized tableted product,as follows 
a pharmaceutical composition in tablet form containing paroxetine,produced on a commercial scale by a process which comprises the steps of 
a dry admixing paroxetine and excipients in a mixer to form a mixture or 
b dry admixing paroxetine and excipients,compressing the resulting combination into a slug material or roller compacting the resulting combination into a strand material,and milling the prepared material into a free flowing mixture and 
c compressing the mixture into tablets.
a pharmaceutical composition in tablet form according to claim containing an amount of paroxetine selected from mg,mg,mg,mg and mg,wherein the amount of paroxetine is expressed as the free base,produced on a commercial scale by a process which comprises the steps of 
a dry admixing paroxetine and excipients in a mixer to form a mixture or 
b dry admixing paroxetine and excipients,compressing the resulting combination into a slug material or roller compacting the resulting combination into a strand material,and milling the prepared material into a free flowing mixture and 
c compressing the mixture into tablets using a single punch or rotary tablet machine.
the general rule of infringement is that every claim limitation or its equivalent must be represented in the accused activity.see hilton davis chem,d each element contained in a patent claim is deemed material in defining the scope of the patented invention.that which infringes if later,anticipates if earlier.peters active manufacturing.yorktowne,t hat which infringes,if later,would anticipate,if earlier quoting peters.these rules,like all rules,have generated exceptions,but the exceptions in connection with anticipation of claim content are rare,and represent a pragmatic adjustment to the needs of science,not law.
such an exception exists for inventions directed to a novel product that,although patentable as a product,can not be adequately described other than by the way it was made the process may or may not itself be novel,but that aspect is deemed irrelevant to the claim to the new product.this exception was created to accommodate the rare circumstances to which it has been applied,as illustrated in in re thorpe,and scripps clinic research foundation genentech.yet the courts,including my colleagues on this panel,do not appear to have understood the role of the exception,as illustrated in the holding in this case.thus my colleagues today adopt a rule for claims with process limitations,a rule that is seriously flawed.instead of taking this opportunity to clarify the confusion surrounding this issue,the court exacerbates it.i must,respectfully,dissent.
claim construction 
the smithkline inventors in the patent describe the production of a stabilized paroxetine tablet by a specified process that reduces or eliminates the formation of a impurity.they claim the commercial paroxetine tablets produced by and limited to the specified process.that is their invention.they do not assert that the claims cover every form of paroxetine however it is produced,and they report that paroxetine is well known.the district court,citing the confusion of conflicting federal circuit precedent,held that the process steps in the claims are not claim limitations,whereby the court held the claim invalid because paroxetine itself is a known compound.
it is not the law that process limitations in product claims are not claim limitations.it is not the law that process limitations are ignored in construing claims,whatever the nature of the invention.claims state the invention for which a patent is sought.see claims state the subject matter which the applicant regards as his invention.all claims are construed in light of the specification the observer looks to the specification to ascertain what has been invented,and understands the claim accordingly.see phillips awh,en banc.this rule is not suspended when product and process limitations appear in the same claim.no 